18F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy

Conclusion: 18F-DCFPyL PET/CT imaging offers high detection rates in biochemically recurrent prostate cancer patients and is positive in about 50% of patients with a PSA level of less than 0.5 ng/mL, which could substantially impact clinical management. In postsurgical patients, 18F-DCFPyL PET/CT correlates with PSA, PSA doubling time, and PSA velocity, suggesting it may have prognostic value. 18F-DCFPyL PET/CT is highly promising for localizing sites of recurrent prostate cancer.

Source: Journal of Nuclear Medicine - June 3, 2020 Category: Nuclear Medicine Authors: Mena, E., Lindenberg, M. L., Turkbey, I. B., Shih, J. H., Harmon, S. A., Lim, I., Lin, F., Adler, S., Eclarinal, P., McKinney, Y. L., Citrin, D., Dahut, W., Wood, B. J., Krishnasamy, V., Chang, R., Levy, E., Merino, M., Pinto, P., Eary, J. F., Choyke, P. Tags: Clinical Source Type: research